Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Roche Holding AG (OTCQX International Premier:RHHBY)

34.22
Delayed Data
As of May 24
 -0.08 / -0.23%
Today’s Change
25.25
Today|||52-Week Range
36.82
+19.94%
Year-to-Date
BioLineRx Makes Regulatory Submission for Trial of BL-8040
May 23 / Zacks.com - Paid Partner Content
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1
May 18 / Zacks.com - Paid Partner Content
Roche's Arthritis Drug Gets FDA Nod for Label Expansion
May 23 / Zacks.com - Paid Partner Content
AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study
May 15 / Zacks.com - Paid Partner Content
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
May 23 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study
May 12 / Zacks.com - Paid Partner Content
Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain
May 22 / Zacks.com - Paid Partner Content
Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat
May 11 / Zacks.com - Paid Partner Content
Merck KGaA (MKGAF) Q1 Earnings Fall Y/Y, Revenues Increase
May 19 / Zacks.com - Paid Partner Content
Puma (PBYI) Q1 Loss Narrows, Focus Remains on Neratinib
May 11 / Zacks.com - Paid Partner Content